Idorsia grabs FDA approval for hypertension drug
2024-03-21
上市批准并购临床2期引进/卖出临床3期
The U.S. FDA has approved Idorsia's oral anti-hypertensive therapy, just months after J&J handed the rights to the drug back to the Swiss biotech.
With the approval, once-daily Tryvio (aprocitentan) becomes the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives.
Idorsia was spun out of Actelion as part of J&J's $30 billion acquisition in 2017. Then, in late 2017, J&J's Janssen Biotech paid $230 million to exercise its option to enter into a collaboration agreement with Idorsia to jointly develop and commercialize aprocitentan. But last September, Janssen decided to return the rights to the drug to Idorsia, along with a $343 million payment.
Tryvio was evaluated as a monotherapy in a phase 2 study in patients with hypertension, and as an add-on therapy in the phase 3 PRECISION study in patients with confirmed resistant hypertension.
Idorsia says it plans to make the treatment available to the millions of patients in the U.S. with hypertension that is not controlled by other drugs in the second half of 2024.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。